Place Raymond Blyckaerts, 13
B-1050 Brussels, Belgium

Opening hours:
Mon to Thu: 10h - 12h30 and 13h30 - 17h
Fri: 10h - 12h30 and 13h30 - 16h


+3226269640
Google maps


Find us on
Google Maps
To subscribe to our newsletter, please click here. If you would like to become an EATG member, please fill in the form here. You can also subscribe to our RSS feed by clicking here.
You can also follow us on one of these media :
TAGS

22/08/2014
CATIE: TreatmentUpdate 203: Brain-related issues

TreatmentUpdate is CATIE's flagship digest on cutting-edge developments in HIV and hepatitis C research and treatment. TreatmentUpdate 203: July 2014 is available at: http://www.catie.ca/en/treatmentupdate/treatmentupdate-203

Read more...

Source Source: CATIE





22/08/2014
CMV co-infection linked to increased risk of heart and stroke problems

As mentioned in our previous CATIE News story , cytomegalovirus (CMV) is a member of the herpes family of viruses. CMV infection is relatively common among adults. For most people, CMV does not cause serious obvious disease. However, among people who have weakened immune systems—such as people who have untreated HIV infection or who use transplant medicines—CMV can cause...

Read more...

Source Source: CATIE





22/08/2014
Canadian researchers point to CMV as a problem for the immune system

The widespread availability of potent anti-HIV combination therapy (commonly called ART or HAART) has led to improved health and prospects of prolonged survival among many HIV-positive people in Canada and other high-income countries. ART works by greatly suppressing production of HIV. This allows the body to begin repairs to the immune system, leading to increased levels of T-cells....

Read more...

Source Source: CATIE





22/08/2014
New TB drug bedaquiline: Weighing the benefits against the risks

Earlier this month, advocates from the Community Research Advisors Group (CRAG)—an international, community-based advisory body working to ensure the engagement of affected communities in tuberculosis (TB) research conducted by the Centers for Disease Control and Prevention (CDC) —published an article in The Lancet offering a community perspective on the use of the...

Read more...

Source Source: Breakthroughs





21/08/2014
Vault nanoparticles engineered at UCLA show promise for cancer treatment and possible HIV cure

UCLA scientists developed a method for placing bryostatin 1 in nanoscale vaults for safe delivery to cells, where it can activate latent HIV, enabling the virus to be eradicated. A multidisciplinary team of scientists from UCLA and Stanford University has used a naturally occurring nanoparticle called a vault to create a novel drug delivery system that could lead to advances in...

Read more...